Biocon expects oral insulin partner by March end

24 Nov 2011 Evaluate

Biocon, country’s largest listed biotechnology company, anticipates a deep-pocketed global partner for its experimental oral insulin pill by end-March. For this the company is in advanced discussions with potential partners.

Earlier in January, Biocon was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes. Also the planned IPO of its contract research organization, Syngene, is on track.

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.

The company’s net profit for the quarter fell 22.05% at Rs 68.07 crore as compared to Rs 87.33 crore for the quarter ended September 30, 2010. Total income has increased by 14.23% to Rs 400.53 crore for the quarter under review from Rs 350.62 crore for the similar quarter of the previous year.

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×